Safety of biologic therapies for the treatment of juvenile idiopathic arthritis

Bibliography

• Berntson L, Andersson Gare B, Fasth A, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003;30:2275-82
   PubMed Web of Science ®Google Scholar
• Danner S, Sordet C, Terzic J, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006;33:1377-81
   PubMed Web of Science ®Google Scholar
• Peterson LS, Mason T, Nelson AM, et al. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing? Arthritis Rheum 1996;39:1385-90
   PubMed Web of Science ®Google Scholar
• Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10:3049-60
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465-82
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, et al. for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Lahdenne P, Vahasalo P, Honkanen V. Infliximab or Etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20
   PubMed Web of Science ®Google Scholar
• Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label Etanercept on extended oligoarticular juvenile idiopathic arthritis. enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the Clipper study. Ann Rheum Dis 2014;73:1114-22
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011;50(1):230-6
   PubMed Web of Science ®Google Scholar
• Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24
   PubMed Web of Science ®Google Scholar
• McCroskery P, Wallace CA, Lovell DJ, et al. Summary of worldwide pediatric malignancies reported after exposure to Etanercept. Pediatr Rheumatol Online J 2010;8:18
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of Etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
   PubMed Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004;63:1638-44
   PubMed Web of Science ®Google Scholar
• Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of Etanercept and methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, et al. [10 years experience in the German JIA Etanercept Registry – lessons from changing patient populations]. Arthritis Rheum 2011;31:334-42
   Google Scholar
• Prince FH, Twil M, Ten Cate R, et al. Long-term follow-up on effectiveness and safety of Etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41
   PubMed Web of Science ®Google Scholar
• Southwood TR, Foster HE, Davidson JE, et al. Duration of Etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011;50:189-95
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of Etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol 2014;41(12):2459-65
   PubMed Web of Science ®Google Scholar
• Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int 2015;35(3):465-70
   PubMed Web of Science ®Google Scholar
• Barthel D, Horneff G. Inflammatory bowel disease in juvenile idiopathic arthritis patients upon biologics [abstract]. Arthritis Rheum 2013;65(Suppl 10):268
   Google Scholar
• Zuber Z, Rutkowska-Sak L, Postepski J, et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit 2011;17:SR35-42
   PubMed Web of Science ®Google Scholar
• Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012;14(5):R230
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R, Tse SML, Horneff G, et al. A double-blind, placebo-controlled, multicenter study of the efficacy and safety of adalimumab in pediatric patients with enthesitis-related arthritis. In press
   Google Scholar
• Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol 2014;33(10):1433-41
   PubMed Web of Science ®Google Scholar
• Horneff G, Ruperto N, Wallace C, et al. Long term safety and effectiveness of Adalimumab in children with moderately to severly active polyarticular or polyarticular course Juvenile Idiopathic Arthritis. Ann Rheum Dis 2014;73(Suppl 2):61-2
   Google Scholar
• Schmeling H, Minden K, Foeldvari I, et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 2014;66(9):2580-9
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 2011;70(9):1605-12
   PubMed Web of Science ®Google Scholar
• Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, et al. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. J Rheumatol 2014;41(7):1409-15
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802
   PubMed Web of Science ®Google Scholar
• Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012;22(1):109-15
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014;41(4):759-67
   PubMed Web of Science ®Google Scholar
• Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathiy arthritis. N Engl J Med 2012;367:2385-95
   PubMed Web of Science ®Google Scholar
• Horneff G, Huppertz HI, Ganser G, et al. Drug safety in treatment of juvenile idiopathic arthritis (JIA): biologic therapy compared with MTX. Arthritis Rheum 2014;66:Suppl:S121
   Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2396-406
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with Etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;3850-5
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2014. [ Epub ahead of print]
   Google Scholar
• Horneff G, Becker I. On behalf of German and Austrian Collaborative BIKER study group. Serious infections in Juvenile Idiopathic Arthritis patients upon TNF inhibitors depend on disease activity. Arthritis Rheum 2014;73(suppl 2):114-5
   Google Scholar
• Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(8):2773-80
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301(7):737-44
   PubMed Web of Science ®Google Scholar
• van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with Etanercept. J Rheumatol 2011;38:1441-6
   PubMed Web of Science ®Google Scholar
• Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with Etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49:1694-8
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomised, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Heinz C, Edelsten C, et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013;21(3):180-91
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013;21(1):12-20
   Web of Science ®Google Scholar
• Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of Etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53(1):18-23
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63(4):612-18
   PubMed Web of Science ®Google Scholar
• Anink J, Otten MH, Gorter SL, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford) 2013;52(9):1674-9
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006;149(6):833-6
   PubMed Web of Science ®Google Scholar
• Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62(12):3776-82
   PubMed Web of Science ®Google Scholar
• Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(4):1263-71
   PubMed Web of Science ®Google Scholar
• Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008;280-8 10.1182/asheducation-2008.1.280
   PubMedGoogle Scholar
• Cron R, Beukelman T. Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23
   PubMed Web of Science ®Google Scholar